Pimonidazole hydrochloride

Phase 2Small molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

Pimonidazole hydrochloride is one of 152 small molecule programs targeting Gastric Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

151

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric AdenocarcinomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

TuberculosisActive, not recruiting

HypoxiaActive, not recruiting

Gastric AdenocarcinomaPreclinical

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

TuberculosisPhase 2

Active, not recruiting

HypoxiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Metastatic Melanoma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

23 2

DTIC-Dome

Bayer

Phase 3

17 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

46 4

Taxol

Teva

Phase 3

7 5

Mektovi

Pfizer

Phase 3

7 6

Braftovi

Pfizer

Phase 3

6 7

Cotellic

Roche

Phase 3

6 8

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

17 9

Fabhalta

Regeneron

Phase 3

1 10

Libtayo

Regeneron

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Recruiting

Gastric Adenocarcinoma

NCT06669663

Clinical

Trials by Indication[1]

Gastric Adenocarcinoma1 trial

Hypoxia Driven Metabolic Response in Oesophagogastric Adenocarcinoma

Recruiting·IImperial College London··NCT06669663·120 enrolled

Metastatic Melanoma1 trial

Biomarker Correlates of Hypoxia in Metastatic Melanoma

Withdrawn·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02061007

Hypoxia1 trial

Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride

Completed·TThomas Gleason·Phase 1·NCT03410420·9 enrolled

Tuberculosis1 trial

Pimonidazole Hydrochloride to Detect Low Oxygen in Tuberculosis-Infected Lungs

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00374517

Pancreatic Cancer1 trial

A Clinical Trial of Intratumoral Hypoxia and Its Biologic Correlates in Patients Undergoing Surgical Resection of Localized Pancreatic Cancer, Using Pre-operative Administration of the Hypoxia Marker Pimonidazole.

Completed·UUniversity Health Network, Toronto··NCT01248637·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Pimonidazole hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pimonidazole hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pimonidazole hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Pimonidazole hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Gastric Adenocarcinoma1 trial

Metastatic Melanoma1 trial

Hypoxia1 trial

Tuberculosis1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News